Skip to main content

Table 1 Baseline characteristics of hip and isolated greater trochanter fracture patients

From: Isolated greater trochanter fracture may impose a comparable risk on older patients’ survival as a conventional hip fracture: a population-wide cohort study

 

Total

n = 11,541

Hip fracture

n = 11,491

Isolated greater trochanter fracture

n = 50

P-value

Age

81 (73–87)

81 (73–87)

78 (65–87)

0.4

Age group

 50–59

801 (6.9)

791 (6.9)

10 (20.0)

0.006

 60–69

1,411 (12.2)

1,406 (12.2)

5 (10.0)

 

 70–79

2,954 (25.6)

2,943 (25.6)

11 (22.0)

 

 80–89

4,881 (42.3)

4,865 (42.3)

16 (32.0)

 

 90 + 

1,494 (12.9)

1,486 (12.9)

8 (16.0)

 

Females

8,278 (71.7)

8,245 (71.8)

33 (66.0)

0.4

Fracture type

   

 < 0.001

 Femoral neck

5,883 (51.0)

5,883 (51.2)

0 (0.0)

 

 Pertrochanteric

4,953 (42.9)

4,953 (43.1)

0 (0.0)

 

 Subtrochanteric

655 (5.7)

655 (5.7)

0 (0.0)

 

 Isolated greater trochanter fracture

50 (0.4)

0 (0.0)

50 (100)

 

Charlson Comorbidity Index

 0

4,510 (39.1)

4,495 (39.1)

15 (30.0)

0.4

 1–2

4,147 (35.9)

4,127 (35.9)

20 (40.0)

 

  ≥ 3

2,884 (25.0)

2,869 (25.0)

15 (30.0)

 

Comorbidities

 Myocardial infarction

802 (6.9)

796 (6.9)

6 (12.0)

0.2

 Congestive heart failure

5,052 (43.8)

5,025 (43.7)

27 (54.0)

0.14

 Peripheral vascular disease

1,207 (10.5)

1,197 (10.4)

10 (20.0)

0.03

 Cerebrovascular disease

2,484 (21.5)

2,477 (21.6)

7 (14.0)

0.2

 Dementia

1,112 (9.6)

1,106 (9.6)

6 (12.0)

0.6

 Chronic pulmonary disease

1,248 (10.8)

1,243 (10.8)

5 (10.0)

0.9

 Rheumatic disease

384 (3.3)

383 (3.3)

1 (2.0)

0.6

 Peptic ulcer disease

546 (4.7)

542 (4.7)

4 (8.0)

0.3

 Mild liver disease

174 (1.5)

174 (1.5)

0 (0.0)

0.4

 Diabetes without chronic complication

1,251 (10.8)

1,242 (10.8)

9 (18.0)

0.1

 Diabetes with chronic complication

683 (5.9)

678 (5.9)

5 (10.0)

0.2

 Hemi- or paraplegia

534 (4.6)

530 (4.6)

4 (8.0)

0.3

 Renal disease moderate/severe

469 (4.1)

465 (4.0)

4 (8.0)

0.2

 Any malignancy

1,184 (10.3)

1,179 (10.3)

5 (10.0)

 > 0.9

 Moderate/severe liver disease

36 (0.3)

36 (0.3)

0 (0.0)

0.7

 Metastatic solid tumor

42 (0.4)

42 (0.4)

0 (0.0)

0.7

 AIDS/HIV

1 (0.0)

1 (0.0)

0 (0.0)

0.9

  1. Continuous variables are shown as median (25th-75th percentile) and proportions as n (%)
  2. P-values are based on the Mann Whitney U-test for continuous variables and the Pearson’s chi-squared test for categorical variables